SG10202003296VA - Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies - Google Patents

Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Info

Publication number
SG10202003296VA
SG10202003296VA SG10202003296VA SG10202003296VA SG10202003296VA SG 10202003296V A SG10202003296V A SG 10202003296VA SG 10202003296V A SG10202003296V A SG 10202003296VA SG 10202003296V A SG10202003296V A SG 10202003296VA SG 10202003296V A SG10202003296V A SG 10202003296VA
Authority
SG
Singapore
Prior art keywords
mbs
migraine
treatment
cgrp antibodies
bothersome symptom
Prior art date
Application number
SG10202003296VA
Inventor
Roger Cady
Jeffrey T L Smith
Joseph Hirman
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SG10202003296VA publication Critical patent/SG10202003296VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG10202003296VA 2020-04-06 2020-04-09 Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies SG10202003296VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063005950P 2020-04-06 2020-04-06

Publications (1)

Publication Number Publication Date
SG10202003296VA true SG10202003296VA (en) 2021-11-29

Family

ID=70457082

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202003296VA SG10202003296VA (en) 2020-04-06 2020-04-09 Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Country Status (9)

Country Link
US (2) US20210309725A1 (en)
JP (1) JP2023531120A (en)
KR (1) KR20210124867A (en)
AU (1) AU2020202454A1 (en)
BR (1) BR102020007149A8 (en)
CA (1) CA3077973A1 (en)
MX (2) MX2020004652A (en)
SG (1) SG10202003296VA (en)
WO (1) WO2021205216A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018226811A1 (en) * 2017-03-02 2019-09-26 Beth Israel Deaconess Medical Center, Inc. Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO2008144763A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
SG194973A1 (en) * 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
HUE054437T2 (en) 2011-05-20 2021-09-28 H Lundbeck As Anti-cgrp compositions and use thereof
JP6502337B2 (en) 2013-07-03 2019-04-17 アルダー・バイオファーマシューティカルズ・インコーポレーテッド Regulation of glucose metabolism using anti-CGRP antibody
CN106456759A (en) * 2014-03-21 2017-02-22 泰华制药国际有限公司 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
BR112020018192A2 (en) * 2019-01-08 2021-08-24 H. Lundbeck A/S Acute and rapid treatment of headaches using anti-cgrp antibodies

Also Published As

Publication number Publication date
US20210309725A1 (en) 2021-10-07
MX2020008262A (en) 2021-10-07
MX2020004652A (en) 2021-10-07
BR102020007149A8 (en) 2023-09-26
US20240101653A1 (en) 2024-03-28
AU2020202454A1 (en) 2021-10-21
WO2021205216A1 (en) 2021-10-14
JP2023531120A (en) 2023-07-21
CA3077973A1 (en) 2021-10-06
BR102020007149A2 (en) 2021-12-07
KR20210124867A (en) 2021-10-15

Similar Documents

Publication Publication Date Title
GEP20207162B (en) Lag-3-binding molecules and methods of use thereof
MX2017012802A (en) Anti-sortilin antibodies and methods of use thereof.
PE20161392A1 (en) COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCTION, AND ITS USES
TW201613970A (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
MX2021015309A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same.
MX2018008339A (en) Recombinant igg fc multimers.
EA201890640A1 (en) RECOMBINANT VECTORS CONTAINING PEPTIDE 2A
MX363209B (en) Cgrp antibodies.
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
PE20181054A1 (en) HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE
IL284683A (en) Acute treatment and rapid treatment of headache using anti-cgrp antibodies
EA201391170A1 (en) THERAPEUTIC MEANS BASED ON YEAST FOR THE TREATMENT OF CHRONIC HEPATITIS B
MX2019010397A (en) Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide.
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
PH12015502164A1 (en) Flavivirus neutralizing antibodies and methods of use thereof
EA202090457A1 (en) COMBINED THERAPY BY LASMIDITAN AND CGRP ANTAGONIST FOR APPLICATION IN THE TREATMENT OF MIGRAINE
MX2016012788A (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage.
EA201891925A1 (en) ANTIBODIES TO CD40 WITH STRENGTHENED AGONISTIC ACTIVITY
IL284677A (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
MX2020010269A (en) Methods of treating ulcerative colitis.
SG10202003296VA (en) Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
MX2020013428A (en) Monoclonal antibodies against human tim-3.
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2022008255A (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies.
MX2019002382A (en) Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension.